ProQR Therapeutics N.V.
PRQR
Positions held
Your positionsPRQR isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $221.56M | Enterprise value | $119.75M | Trailing P/E | — | Forward P/E | -3.32 |
| PEG | — | Price / book | 2.48 | Beta | 0.20 | Dividend yield | 0.00% |
| Revenue growth | 120.4% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -100.7% |
| Profit margin | -2.3% | ROE | -57.4% | ROA | -19.8% | Debt / equity | 0.19 |
| Current ratio | 3.49 | Free cash flow | -$19.07M | Analyst recommendation | strong_buy | Mean target | $7.78 |
| 52w high | $3.10 | 52w low | $1.33 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $8.8M | $2.0M | $4.7M | $2.9M | $3.8M | — |
| Op margin | -100.7% | -671.4% | -194.0% | -391.5% | -320.9% | — |
| Net income | -$8.7M | -$13.4M | -$8.9M | -$11.0M | -$12.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$8.8M | -$13.6M | -$9.1M | -$11.3M | -$12.2M | — |
- Revenue +331% vs prior quarter ($8.8M vs $2.0M).
- Operating margin expanded to -100.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $15.9M | $18.9M | $6.5M | $3.6M | — |
| Op margin | -273.1% | -161.2% | -534.1% | -1813.0% | — |
| Net income | -$42.2M | -$27.8M | -$28.1M | -$64.4M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$43.4M | -$30.5M | -$34.8M | -$65.2M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease
2026-09-09 · ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment
2026-09-02 · ProQR to Participate in Upcoming Investor Conferences in September 2026
2026-08-14 · ProQR: Q2 Earnings Snapshot
2026-08-14 · Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
2026-08-13 · ProQR Announces Second Quarter 2026 Operating and Financial Results
2026-08-03 · Proqr Therapeutics Insider Bought Shares Worth $353,960, According to a Recent SEC Filing
Price (daily)
Full chart · RSI · MACD · patterns